Cadila Healthcare witnessed a rise in share price on Tuesday after the company's formulations manufacturing facility at Baddi has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA).

This receipt of EIR indicates the successful closure of the inspection points (483s) raised based on the inspection carried out between February 21, 2017 to March 01, 2017.

Shares of Cadila Healthcare are trading at Rs 502, up Rs 11.5, or 2.34% at the Bombay Stock Exchange (BSE) on Tuesday at 9:51 a.m.

The scrip has touched an intra-day high of Rs 510 and low of Rs 500.80. The total volume of shares traded at the BSE is 93,096.

Total volume of shares traded on the bourses today was lower by 38.25% to 847,296 compared with 22-day average volume of 1,372,031.